Testing actimab-A and cemiplimab for recurring glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests combining two drugs, actimab-A and cemiplimab, for people whose glioblastoma has come back after prior treatment. The goal is to see if this combination can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with glioblastoma that has come back after first or second relapse.
- Your tumor has specific markers (IDH wild type) and MGMT methylation status has been checked.
- You have had radiation therapy at least 6 months ago (if high dose) or 3 months ago (if lower dose).
- You have not been treated with certain immune therapies (anti-PD1, PDL1, CTLA-4) before.
- You are in generally good health with adequate organ function (kidney, liver, blood counts).
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (retifanlimab), a targeted drug (bevacizumab), and low-dose radiation for people whose glioblastoma has come back. The goal is to see if this treatment can help shrink or slow the tumor.
This trial tests a combination of two drugs (D2C7-IT and 2141-V11) given directly into the brain after surgery for people with recurrent glioblastoma. The goal is to see if this treatment is safe and can help control the tumor.
This trial tests a combination of two drugs, triapine and temozolomide, for people whose glioblastoma has come back after initial treatment. The goal is to see if this combination can help control the tumor.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This trial combines two immunotherapy drugs (ipilimumab and nivolumab) given through a vein and directly into the brain for people with recurrent glioblastoma. The goal is to see if this approach can help control the tumor.
This trial tests a combination of low-dose radiation, an immunotherapy drug (sintilimab), and chemotherapy (temozolomide) for people with glioblastoma that has come back. The goal is to see if this approach can help control the tumor and improve survival.
Hear when a new Recurrent Glioblastoma, IDH-Wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.